141 related articles for article (PubMed ID: 37454916)
1. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Roskoski R
Pharmacol Res; 2023 Aug; 194():106847. PubMed ID: 37454916
[TBL] [Abstract][Full Text] [Related]
2. Rule of five violations among the FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2023 May; 191():106774. PubMed ID: 37075870
[TBL] [Abstract][Full Text] [Related]
3. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.
Roskoski R
Pharmacol Res; 2024 Jan; 199():107036. PubMed ID: 38096958
[TBL] [Abstract][Full Text] [Related]
4. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of protein kinase inhibitors for cancer therapy.
Kannaiyan R; Mahadevan D
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1249-1270. PubMed ID: 30259761
[TBL] [Abstract][Full Text] [Related]
6. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
[TBL] [Abstract][Full Text] [Related]
7. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
Latham BD; Geffert RM; Jackson KD
Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
[TBL] [Abstract][Full Text] [Related]
8. Development of Kinase-Centric Drugs: A Computational Perspective.
Pratap Reddy Gajulapalli V
ChemMedChem; 2023 Oct; 18(19):e202200693. PubMed ID: 37442809
[TBL] [Abstract][Full Text] [Related]
9. Protein kinases: drug targets for immunological disorders.
Castelo-Soccio L; Kim H; Gadina M; Schwartzberg PL; Laurence A; O'Shea JJ
Nat Rev Immunol; 2023 Dec; 23(12):787-806. PubMed ID: 37188939
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015.
O Brien Z; Moghaddam MF
Curr Med Chem; 2017; 24(29):3159-3184. PubMed ID: 28545370
[TBL] [Abstract][Full Text] [Related]
11. Evaluating physiochemical properties of FDA-approved orally administered drugs.
Reese TC; Devineni A; Smith T; Lalami I; Ahn JM; Raj GV
Expert Opin Drug Discov; 2024 Feb; 19(2):225-238. PubMed ID: 37921049
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinases and their Inhibitors Implications in Modulating Disease Progression.
Ahsan R; Khan MM; Mishra A; Noor G; Ahmad U
Protein J; 2023 Dec; 42(6):621-632. PubMed ID: 37768476
[TBL] [Abstract][Full Text] [Related]
13. Absorption matters: A closer look at popular oral bioavailability rules for drug approvals.
Caminero Gomes Soares A; Marques Sousa GH; Calil RL; Goulart Trossini GH
Mol Inform; 2023 Nov; 42(11):e202300115. PubMed ID: 37550251
[TBL] [Abstract][Full Text] [Related]
14. In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases.
Wells CI; Kapadia NR; Couñago RM; Drewry DH
Medchemcomm; 2018 Jan; 9(1):44-66. PubMed ID: 30108900
[TBL] [Abstract][Full Text] [Related]
15. CDK Inhibitors and FDA: Approved and Orphan.
Cicenas J; Simkus J
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672637
[TBL] [Abstract][Full Text] [Related]
16. Neural crest cells and fetal alcohol spectrum disorders: Mechanisms and potential targets for prevention.
Chen SY; Kannan M
Pharmacol Res; 2023 Aug; 194():106855. PubMed ID: 37460002
[TBL] [Abstract][Full Text] [Related]
17. Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth.
Maresca L; Crivaro E; Migliorini F; Anichini G; Giammona A; Pepe S; Poggialini F; Vagaggini C; Giannini G; Sestini S; Borgognoni L; Lapucci A; Dreassi E; Taddei M; Manetti F; Petricci E; Stecca B
Pharmacol Res; 2023 Sep; 195():106858. PubMed ID: 37473878
[TBL] [Abstract][Full Text] [Related]
18. HPV E7-drived ALKBH5 promotes cervical cancer progression by modulating m6A modification of PAK5.
Huo FC; Zhu ZM; Du WQ; Pan YJ; Jiang X; Kang MJ; Liu BW; Mou J; Pei DS
Pharmacol Res; 2023 Sep; 195():106863. PubMed ID: 37480971
[TBL] [Abstract][Full Text] [Related]
19. Expanding germ-organ theory: Understanding non-communicable diseases through enterobacterial translocation.
Boopathi S; Priya PS; Haridevamuthu B; Nayak SPRR; Chandrasekar M; Arockiaraj J; Jia AQ
Pharmacol Res; 2023 Aug; 194():106856. PubMed ID: 37460001
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the management and implementation of care for familial hypercholesterolaemia.
Lan NSR; Bajaj A; Watts GF; Cuchel M
Pharmacol Res; 2023 Aug; 194():106857. PubMed ID: 37460004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
